Your browser doesn't support javascript.
loading
Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.
Pyankov, Oleg V; Setoh, Yin Xiang; Bodnev, Sergey A; Edmonds, Judith H; Pyankova, Olga G; Pyankov, Stepan A; Pali, Gabor; Belford, Shane; Lu, Louis; La, Mylinh; Lovrecz, George; Volchkova, Valentina A; Chappell, Keith J; Watterson, Daniel; Marsh, Glenn; Young, Paul R; Agafonov, Alexander A; Farmer, Jillann F; Volchkov, Victor E; Suhrbier, Andreas; Khromykh, Alexander A.
Afiliação
  • Pyankov OV; State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
  • Setoh YX; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Bodnev SA; State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
  • Edmonds JH; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Pyankova OG; State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
  • Pyankov SA; State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
  • Pali G; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Belford S; Plasvacc Pty. Ltd., Kalbar, QLD, Australia.
  • Lu L; Bio Medical Manufacturing, Fermentation and Protein Production Facility, CSIRO, Clayton, VIC, Australia.
  • La M; Bio Medical Manufacturing, Fermentation and Protein Production Facility, CSIRO, Clayton, VIC, Australia.
  • Lovrecz G; Bio Medical Manufacturing, Fermentation and Protein Production Facility, CSIRO, Clayton, VIC, Australia.
  • Volchkova VA; Molecular Basis of Viral Pathogenicity, CIRI, INSERM, U1111-CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, France.
  • Chappell KJ; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Watterson D; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Marsh G; Australian Animal Health Laboratory, CSIRO Health and Biosecurity, Geelong, VIC, Australia.
  • Young PR; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
  • Agafonov AA; State Center for Virology and Biotechnology Vector, Koltsovo, Russian Federation.
  • Farmer JF; United Nations Medical Service, New York, NY 10017, USA.
  • Volchkov VE; Molecular Basis of Viral Pathogenicity, CIRI, INSERM, U1111-CNRS UMR5308, Université de Lyon, Université Claude Bernard Lyon 1, Ecole Normale Supérieure de Lyon, France.
  • Suhrbier A; QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Khromykh AA; Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Brisbane, QLD, Australia.
Sci Rep ; 7: 41537, 2017 02 03.
Article em En | MEDLINE | ID: mdl-28155869
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Doença pelo Vírus Ebola / Ebolavirus / Profilaxia Pós-Exposição / Anticorpos Antivirais / Antígenos Virais Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Doença pelo Vírus Ebola / Ebolavirus / Profilaxia Pós-Exposição / Anticorpos Antivirais / Antígenos Virais Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article